Summary :
AbbVie has terminated its collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
BioArctic has already announced the news through its own press release, whereas AbbVie is yet to make an official statement on its website. BioArctic’s portfolio of potential treatments for Parkinson’s disease, particularly products that work against alpha-synuclein, whose mutations and aggregates produce deposits that are hallmarks of the disorder, was the subject of a research agreement between the two companies in 2016, with the goal of developing and commercialising BioArctic’s portfolio of potential treatments for Parkinson’s disease, particularly products that work against alpha-synuclein, whose mutations and aggregates produce deposits that
The businesses started a Phase I trial for ABBV-0805 in 2019, and the results were presented at an international conference in 2021, with promising results encouraging a Phase II research. Shortly before the study began, the US Food and Drug Administration accepted its Investigational New Drug (IND) application. The clinical development of ABBV-0805 has been managed and funded by AbbVie.
Statement From BioArtics
“We are disappointed that AbbVie has taken this decision. All available data indicates that ABBV-0805 has uniquely high selectivity for the pathological forms of aggregated alpha-synuclein, as well as Phase 1 data supporting progression to Phase 2. We believe that ABBV-0805 has the potential to become a disease-modifying treatment for people with Parkinson’s disease and will now investigate options to continue the development of this asset,” commented Gunilla Osswald, CEO of BioArctic.
About ABBV-0805
- ABBV-0805, previously called BAN0805, is being studied for Parkinson’s disease, but its scope may extend to cover other movement disorders, such as multiple system atrophy and Lewy body dementia. The goal of the research is to find and develop a new treatment that can slow down or stop Parkinson’s disease progression.
- ABBV-0805 is a monoclonal antibody drug candidate that is created to selectively bind and remove aggregated forms of alpha-synuclein such as oligomers and protofibrils, which are found in neurodegenerative conditions like Parkinson’s disease.
- The aim is to design a disease-altering treatment that can stop or decrease the progression of Parkinson’s disease.
Type of Molecule :Biologic
Target :alpha-synuclein
When the two companies began their research contract in 2016, AbbVie then had the right to acquire a licence for the development and commercialisation of BioArctic’s portfolio of alpha-synuclein antibodies for Parkinson’s disease and other conditions.
AbbVie exercised this option in late 2018 and in 2019 a phase 1 study of ABBV-0805 was initiated, with AbbVie managing and funding the clinical development of the monoclonal antibody. The scope of ABBV-0805 may be expanded to include Lewy body dementia and multiple system atrophy.
